Rheumatoid Arthritis Clinical Trial
Official title:
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
Verified date | April 2013 |
Source | Chugai Pharma Taiwan |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan : Food and Drug Administration |
Study type | Interventional |
24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.
Status | Completed |
Enrollment | 72 |
Est. completion date | April 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Patients who had completed at least 5 out of the 7 visits scheduled for weeks 2, 4, 8, 12, 16, 20 and 24 in the tocilizumab Phase IIIb study(MRA230TW). - Patients assigned in the Phase IIIb study(MRA230TW), who had received scheduled dose for at least 16 weeks but still failed to achieve adequate treatment response characterized by ACR20 Exclusion Criteria: - Patients who have received a major surgery including joint surgery 8 weeks prior to the screening or are scheduled to be operated within 6 months after the enrolment. - Patients with rheumatoid autoimmune disease other than RA, including but not limited to SLE(system lupus erythematosus), or significant systemic involvement secondary to RA. - Patients who belong to the Class IV of the ACR classification criteria for functional status of RA. (ACR Amended Criteria for the Classification of Functional Capacity in Rheumatoid Arthritis; Class IV: Largely or wholly incapacitated with patient bedridden or confined to wheel chair, permitting little or no self-care). - Patients with a history of hypersensitivity to human, humanized or murine monoclonal antibodies or patients with contraindication for them. - Patients who currently have or have a history of recurrence of bacterial, viral,fungal, or mycobacterial infections or other infectious diseases; tuberculosis(TB),atypical mycobacterial disease, clinically significant granulomatous disease on chest radiograph, hepatitis B, hepatitis C, or herpes zoster and etc. However, a patient with hand & foot fungal infections can participate. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | Buddhist Dalin Tzu Chi General Hospital | Chiayi | |
Taiwan | Chang Gung Memorial Hospital -Kaohsiung | Kaohsiung | |
Taiwan | Kaohsiung Medical University Hospital | Kaohsiung | |
Taiwan | Kaohsiung Veterans General Hospital | Kaohsiung | |
Taiwan | Chung Shan Medical University Hospital | Taichung | |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | Cathay General Hospital | Taipei | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
Taiwan | Tri-Service General Hospital | Taipei | |
Taiwan | Chang Gung Memorial Hospital - Linkou | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Chugai Pharma Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with an American College of Rheumatology 70 (ACR70) response | at week 24 | No | |
Secondary | Proportion of patients with ACR50 response | at week 24 | No | |
Secondary | Proportion of patients with ACR20 response | at week 24 | No | |
Secondary | Mean change from baseline of Swollen joint count(SJC) and Tender joint count(TJC) respectively | at baseline and week 24 | No | |
Secondary | Mean change from baseline in disease activity using 28-joint modified disease activity score (DAS28) | at baseline and week 24 | No | |
Secondary | Proportion of patients achieving DAS28 remission (DAS28 < 2.6) | at week 24 | No | |
Secondary | Adverse event incidence | from baseline to week 24 | Yes | |
Secondary | Mean change from baseline to evaluation visits in vital signs | from baseline to week 24 | Yes | |
Secondary | Change in Electrocardiogram. From baseline to evaluation visits | from baseline to week 24 | Yes | |
Secondary | Mean change from baseline visit to evaluation visits in quantitative hematological exam results. | from baseline to week 24 | Yes | |
Secondary | Mean change from baseline visit to evaluation visits in quantitative Biochemical exam of blood results. | from baseline to week 24 | Yes | |
Secondary | Mean change from baseline visit to evaluation visits in quantitative serum lipid exam results. | from baseline to week 24 | Yes | |
Secondary | Mean change from baseline visit to evaluation visits in quantitative urinalysis results. | from baseline to week 24 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |